Physician-Patient Alliance for Health & Safety Announces Availability of Webinar About Respiratory Compromise -- a Potentially Deadly and Avoidable Condition
The webinar features the following clinicians from CUMC:
Paul Boerem, ACNP, RT, Critical Care Nurse Practitioner and Certified Respiratory Therapist, Department of Medicine, Pulmonary, Allergy and Critical Care;
Monica P. Goldklang, MD, Assistant Professor of Medicine (in Anesthesiology) Department of Anesthesiology, Critical Care Medicine;
Steven E. Miller, MD, Assistant Professor of Anesthesiology (Moderator) Department of Anesthesiology, Critical Care Medicine; and
Amanda J. Powers, MD, Assistant Professor of Surgery (in Anesthesiology) Department of Surgery, Acute Care
The Respiratory Compromise Institute (RCI) ? a diverse coalition of 14 medical and safety organizations devoted to raising awareness about the condition ? defines respiratory compromise as a state in which there is a high likelihood of decompensation into respiratory insufficiency, respiratory failure or death, but in which specific interventions (enhanced monitoring and/or therapies) might prevent or mitigate decompensation.
"This webinar highlights how respiratory compromise is a serious, potentially deadly patient safety issue that may be avoidable when proper prevention and identification strategies are used, and when healthcare providers are equipped with comprehensive patient monitoring technology," explains Michael Wong, JD, Executive Director, PPAHS. "Education about the condition and how it can be prevented is vital to reducing its incidence. We encourage all clinicians to view the webinar to learn how they can provide the safest possible care for their patients, particularly those with risk factors that may increase their chances of developing respiratory compromise."
Risk factors for respiratory compromise include obstructive sleep apnea, older age, obesity and chronic obstructive pulmonary disease1-2, in addition to receiving opioid administration.3
The webinar was made possible through an educational grant from Medtronic plc, one of the world's largest medical technology, services and solutions companies.
About Physician-Patient Alliance for Health & Safety
Physician-Patient Alliance for Health & Safety is a non-profit 501(c)(3) whose mission is to promote safer clinical practices and standards for patients through collaboration among healthcare experts, professionals, scientific researchers, and others, to improve healthcare delivery. For more information, please go to www.ppahs.org.
REFERENCES
Frederickson TW, Gordon DB, De Pinto M, et al. Reducing Adverse Drug Events Related to Opioids Implementation Guide. Philadelphia: Society of Hospital Medicine, 2015.
Karcz M, Papadakos PJ. Respiratory complications in the postanesthesia care unit: A review of pathophysiological mechanisms. Can J Respir Ther. 2013;49(4):21-29.
Jarzyna D, Jungquist CR, Pasero C, et al. American society for pain management nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs. 2011;12(3):118-145. doi: 10.1016/j.pmn.2011.06.008.
SOURCE Physician-Patient Alliance for Health & Safety (PPAHS)
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ? Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...